


induce proteasome-degradation of an unknown restriction factor to facilitate reverse transcription of the viral genome. It was demonstrated that degradation of the unknown factor involves formation of a Cul4-DDB1-DCAF1 E3 ligase complex (Sharova et al., 2008; Bergamaschi et al., 2009; Kaushik et al., 2009). Considerable effort was subsequently directed toward identification of the unknown factor, and in 2011 SAMHD1 was identified as the MDM host factor from co-immunoprecipitation studies of Vpx expressed in THP-1 cells and in 293T cells (Hrecka et al., 2011; Laguette et al., 2011). SAMHD1 has a tandem sterile alpha motif (SAM) and HD domain with potential phosphohydrolase activity. The SAMHD1 protein was initially identified from MDDCs as a homolog of mouse interferon- γ -induced protein (Li et al., 2000), and is upregulated in response to viral infection (Prehaud et al., 2005; Hartman et al., 2007; Zhao et al., 2008). Furthermore, SAMHD1 is believed to be involved in regulating cellular intrinsic antiviral responses (Rice et al., 2009).

The identification of SAMHD1 as a target of Vpx was not sufficient to explain all the related phenomena, suggesting the involvement of another factor (Hrecka et al., 2011; Planelles, 2011). However, based on reports indicating that SAMHD1 is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase (Goldstone et al., 2011; Powell et al., 2011), it was hypothesized that SAMHD1 degrades dNTPs (which are small molecule components of viral genomic cDNA) in order to deprive viruses of dNTPs by keeping their concentration low. Lahouassa et al. (2012) recently demonstrated the validity of this hypothesis (Figures 1 and 2). Thus, the additional factor targeted by Vpx appears to be dNTPs. Although dNTPs are utilized for reverse transcription in the cytosol, they are small enough to freely diffuse through nuclear pores in and out of the nucleus. Since SAMHD1 is a nuclear protein (Rice et al., 2009), it is most likely that the concentration of dNTPs in the cytosol is controlled by SAMHD1 in the nucleus. In fact, it was suggested that Vpx-mediated degradation of SAMHD1 is initiated in the nucleus (Brandariz-Nuñez et al., 2012; Figure 2).



In addition to being components of the viral genome, dNTPs are components of the host genome; thus, proliferative CD4⁺ T cells do not express SAMHD1, and maintain the concentration of dNTPs at an optimal level for cell proliferation (2–4 μ M; Lahouassa et al., 2012). In contrast, since MDMs do not proliferate, they do not require high levels of dNTPs, and the low dNTP levels (20–40 nM) resulting from SAMHD1-mediated degradation are therefore not harmful to MDMs (Lahouassa et al., 2012). HIV-2-type viruses carry Vpx for proteasome-mediated degradation of SAMHD1 in order to facilitate replication in MDMs. In contrast, HIV-1 does not require Vpx in order to replicate in MDMs (Fujita et al., 2010) because its reverse transcriptase (RT) is capable of catalyzing viral cDNA synthesis from very low levels of dNTPs (Diamond et al., 2004; Lahouassa et al., 2012). The activity of HIV-2 RT is probably lower [Michaelis constant (K_m) of HIV-2 RT is higher] than that of HIV-1 RT, and therefore, to overcome this disadvantage, HIV-2-type viruses may have evolved to carry Vpx.

We previously mapped the functional region of Vpx involved in viral replication in MDMs (Fujita et al., 2008a,b; Figure 3). It is known that the region in major helix 3 containing amino acids Q⁷⁶



and P⁸⁰ interacts with DCAF1, a subunit of the Cullin4-based E3 ubiquitin ligase complex (Srivastava et al., 2008). This region could overlap with a region that is critical for virion incorporation (Park and Sodroski, 1995; Jin et al., 2001). Gramberg et al. (2010) suggested that another region, which includes amino acids P⁹, N¹², E¹⁵, E¹⁶, and T¹⁷ in the N-terminal loop, binds to a restriction factor; this region was later confirmed to be a SAMHD1-binding region (Ahn et al., 2012).

We also identified several other functional regions in Vpx, including a central region located between major helix 1 and major helix 2, and a polyproline motif in a loop in the C-terminus (Fujita et al., 2008a,b). We revealed that the C-terminal polyproline motif is critical for stable expression of Vpx. Although the function of the central region remains unknown, it has been confirmed that this region is not involved in virion incorporation.



Following the identification of SAMHD1, several investigators showed that although some cells such as undifferentiated THP-1 cells express SAMHD1, both the wild-type HIV-2-type virus and its Vpx mutant infect these cells to an equivalent degree (Hrecka et al., 2011; Planelles, 2011). There are several possible explanations for the similar infectivity of wild-type and Vpx mutant viruses: (1) These cells contain large amounts of dNTPs, and thus, even in the presence of SAMHD1 there are sufficient quantities of dNTPs for viral replication, and (2) SAMHD1 does not function in these cells for some as yet unexplained reason. A plausible explanation may be posttranslational modification (phosphorylation, etc.) of the protein. Further study will be required to uncover the molecular basis for this phenomenon.

Around the time SAMHD1 was identified, it was reported that another host restriction factor, APOBEC3A, inhibits HIV-1 infection of MDMs, and that APOBEC3A is degraded by Vpx (Berger et al., 2010, 2011). In addition, APOBEC3A reportedly decreases the amount of viral cDNA synthesized during reverse transcription. Presumably, degradation of SAMHD1 alone is not sufficient to enable reverse transcription to proceed smoothly, and therefore degradation of APOBEC3A is also required for viral replication in MDMs, suggesting that Vpx functions to counteract the antiviral effects of both APOBEC3A and SAMHD1. A comparative study between APOBEC3A and SAMHD1 must be performed in order to establish each protein's contribution to restricting lentivirus infection in myeloid cells.

SAMHD1-INDEPENDENT FUNCTIONS OF Vpx

Prior to the time that Vpx was found to act on reverse transcription (Fujita et al., 2008a; Srivastava et al., 2008), it was thought that Vpx is critical for nuclear import of the viral genome (Fletcher et al., 1996; Pancio et al., 2000), based on the results of non-quantitative polymerase chain reaction (PCR) studies. This notion was supported by the tendency of Vpx to localize in the nucleus when Vpx is transduced to a cell solely (Pancio et al., 2000; Mahalingam et al., 2001). It has been well established that Vpx is critical for reverse transcription in MDMs, but this does not preclude participation of Vpx in nuclear import in these cells. We previously identified several Vpx mutants that are defective in both reverse transcription and nuclear import (Fujita et al., 2010) in MDMs, which suggests that Vpx also enhances nuclear import in these cells. We hypothesize that this function of Vpx is SAMHD1-independent, since it is plausible that there is no connection between the amount of dNTPs and nuclear import. Further investigations are underway in order to determine if this is indeed the case.

In T cells, such as peripheral blood lymphocytes (PBLs), peripheral blood mononuclear cells (PBMCs), and cultured simian cell lines immortalized by Herpesvirus saimiri such as HSC-F and M1.3S cells, HIV-2-type viruses grow well, but Vpx-deletion mutants exhibit defective replication (Guyader et al., 1989; Kappes et al., 1991; Yu et al., 1991; Akari et al., 1992; Gibbs et al., 1994; Kawamura et al., 1994; Tokunaga et al., 1997; Ueno et al., 2003; Doi et al., 2011). These results indicate that Vpx is also important for viral replication in T cells. Dispensability of Vpx for the infection of T cells has been believed by some researchers (Bergamaschi et al., 2009; Belshan et al., 2012), but this belief was probably based on the results of infectious experiments using high-titer virus.

Our research showed that Vpx enhances nuclear import of the viral genome in HSC-F cells, and that the smaller effect of Vpx on reverse transcription was also observed (Ueno et al., 2003; Fujita et al., 2008a; Figure 2). We mapped the region of Vpx involved in viral replication in HSC-F cells (Fujita et al., 2008b; Figure 3) and found that as is the case in MDMs, the central region and the C-terminal polyproline motif are critical for replication. There is also a unique functional region spanning from major helix 3 to the C-terminal loop, but how this region influences infectivity is unclear. The apparent SAMHD1- and DCAF-1-binding regions are not necessary for viral replication in HSC-F cells, in contrast to MDMs. Furthermore, in HSC-F and M1.3S cells, expression of SAMHD1 was below the detectable level (Nomaguchi, M. and Adachi, A., in preparation). Thus, in these cells, Vpx enhances reverse transcription and nuclear import of the viral genome through an unknown SAMHD1-independent mechanism. Not only cultured cell lines, but also primary T cells are considered to have SAMHD1-independent functions, since SAMHD1- and DCAF-1-binding regions are dispensable for viral replication in PBLs (Fujita, M. and Adachi, A., unpublished data).

It has been reported that Vpx is important for SIV infection in monkeys, and the predominantly infected cells are the intraepithelial T lymphocytes rather than myeloid cells such as macrophages (Hirsch et al., 1998; Belshan et al., 2012). The Vpx in T cells is considered to play a significant role in infection by HIV-2-group viruses *in vivo*. Thus, we strongly suggest that SAMHD1-independent functions of Vpx are also important, although almost all the recent Vpx research has focused on SAMHD1-dependent functions.

WHY DO HIV-2 VIRUSES HAVE TWO SIMILAR PROTEINS?

Lim et al. (2012) recently revealed that Vpr, a Vpx-related protein found in HIV-1 and HIV-2-type viruses, is not involved in degradation of SAMHD1. Instead, the Vpr carried by HIV-1 and HIV-2 arrests cells in the G₂ phase of the cell cycle, a function not associated with Vpx (Fletcher et al., 1996; Stivahtis et al., 1997; Fujita et al., 2010; Table 1). This G₂ arrest is known to be induced via formation of a Cul4-DDB1-DCAF1 E3 ligase complex that includes Vpr as an adaptor. Formation of the complex is followed by proteasomal degradation of an unknown cellular target. This pathway is similar to that involving Vpx, which also functions as an adaptor for the Cul4-DDB1-DCAF1 E3 ligase complex to facilitate proteasomal degradation of SAMHD1 (Ahn et al., 2012). Although the virological significance of the Vpr-mediated G₂ arrest has not been determined, this function is likely to be important since it

Table 1 | The roles of Vpx and Vpr in HIV-1 and HIV-2-type viruses.

	HIV-1	HIV-2 type viruses
Reverse transcription at low dNTP concentrations (in MDMs)	Reverse transcriptase (high activity)	Vpx
Induction of G ₂ arrest	Vpr	Vpr
Enhancement of nuclear import	Vpr (?) ^a	Vpx

^aFurther study is required (see text).

is broadly conserved among HIV/SIV. Since the activity of HIV-2 RT is lower than that of the enzyme found in HIV-1-type viruses, HIV-2 may require SAMHD1 degradation in order to increase the concentration of dNTPs, in addition to induction of G₂ arrest.

Both of these functions, SAMHD1 degradation and G₂ arrest, are mediated via the Cul4-DDB1-DCAF1 E3 ligase complex. SIVagm (African Green Monkey) is known to have only one Vpr, which induces both the degradation of SAMHD1 (Lim et al., 2012) and G₂ arrest (Planelles et al., 1996; Stivahtis et al., 1997; Zhu et al., 2001). Lim et al. proposed that in the evolution of HIV/SIVs, neofunctionalization of Vpr to degrade SAMHD1 resulted in the rapid evolution of the SAMHD1 protein, which induced the birth of a similar protein, Vpx (subfunctionalization), to maximize its SAMHD1-targeting capability. Here, we propose another reason why HIV-2 viruses have similar proteins, Vpr and Vpx. It is known that the region of HIV-1 Vpr spanning from major helix 3 to the C-terminal loop (which includes a cluster of basic amino acids) is critical for induction of G₂ arrest (Di Marzio et al., 1995; Selig et al., 1997; Jacquot et al., 2007). This region corresponds to the mechanistically unknown and unique region of Vpx required for replication in HSC-F cells (Figure 3; Khamsri et al., 2006; Fujita et al., 2008b), but the corresponding region in Vpx does not contain a cluster of basic amino acids in the C-terminal loop. Induction of G₂ arrest and enhancement of replication in T cells may be incompatible functions for one protein. The presence of both Vpr and Vpx may facilitate G₂ arrest and enhancement of HIV-2 replication in T cells, but a full explanation as to why HIV-2 has two proteins that are so similar will require further study.

CONCLUSION

Recent findings indicating that Vpx mediates the degradation of SAMHD1 are intriguing, and reveal yet another example of a virus with a means to counteract host defense mechanisms. Table 1 summarizes the roles played by Vpx and Vpr in HIV-1 and HIV-2. HIV-2/SIV Vpx negates the effect of the unique

REFERENCES

- Agostini, I., Popov, S., Hao, T., Li, J. H., Dubrovsky, L., Chaika, O., Chaika, N., Lewis, R., and Bukrinsky, M. (2002). Phosphorylation of Vpr regulates HIV type 1 nuclear import and macrophage infection. *AIDS Res. Hum. Retroviruses* 18, 283–288.
- Ahn, J., Hao, C., Yan, J., DeLucia, M., Mehrens, J., Wang, C., Gronenborn, A. M., and Skowronski, J. (2012). HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. *J. Biol. Chem.* 287, 12550–12558.
- Akari, H., Sakuragi, J., Takebe, Y., Tomonaga, K., Kawamura, M., Fukasawa, M., Miura, T., Shinjo, T., and Hayami, M. (1992). Biological characterization of human immunodeficiency virus type 1 and type 2 mutants in human peripheral blood mononuclear cells. *Arch. Virol.* 123, 157–167.
- Andrew, A., and Strebel, K. (2010). HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. *Mol. Aspects Med.* 31, 407–417.
- Arias, J. E., Iwabu, Y., and Tokunaga, K. (2011). Structural basis for the antiviral activity of BST-2/tetherin and its viral antagonism. *Front. Microbiol.* 2:250. doi:10.3389/fmicb.2011.00250
- Belshan, M., Kimata, J. T., Brown, C., Cheng, X., McCulley, A., Larsen, A., Thippeshappa, R., Hodara, V., Giavedoni, L., Hirsch, V., and Ratner, L. (2012). Vpx is critical for SIVmne infection of pigtail macaques. *Retrovirology* 9, 32.
- Bergamaschi, A., Ayinde, D., David, A., Le Rouzic, E., Morel, M., Collin, G., Descamps, D., Diamond, F., Brun-Vezinet, E., Nisole, S., Margottin-Goguet, F., Pancino, G., and Transy, C. (2009). The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a post-entry block in macrophage infection. *J. Virol.* 83, 4854–4860.
- Berger, A., Münk, C., Schweizer, M., Cichutek, K., Schüle, S., and Flory, E. (2010). Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes. *J. Biol. Chem.* 285, 12248–12254.
- Berger, G., Durand, S., Fargier, G., Nguyen, X.-N., Cordeil, S., Bouaziz, S., Muriaux, D., Darlix, J.-L., and Cimarelli, A. (2011). APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. *PLoS Pathog.* 7, e1002221. doi:10.1371/journal.ppat.1002221
- Brandariz-Núñez, A., Valle-Casuso, J. C., White, T. E., Laguette, N., Benkirane, M., Brojtsch, J., and Diaz-Griffero, F. (2012). Roles of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac. *Retrovirology* 9, 49.
- Di Marzio, P., Choe, S., Ebright, M., Knoblauch, R., and Landau, N. R. (1995). Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr. *J. Virol.* 69, 7909–7916.
- Diamond, T. L., Roshal, M., Jamburuthugoda, V. K., Reynolds, H. M., Merriam, A. R., Lee, K. Y., Balakrishnan, M., Bambara, R. A., Planelles, V., Dewhurst, S., and Kim, B. (2004). Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. *J. Biol. Chem.* 279, 51545–51553.
- Doi, N., Fujiwara, S., Adachi, A., and Nomaguchi, M. (2011). Rhesus M1.3S cells suitable

- for biological evaluation of macaque-tropic HIV/SIV clones. *Front. Microbiol.* 2:115. doi:10.3389/fmicb.2011.00115
- Fletcher, T. M. III, Brichacek, B., Sharova, N., Newman, M. A., Stivahtis, G., Sharp, P. M., Emerman, M., Hahn, B. H., and Stevenson, M. (1996). Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). *EMBO J.* 15, 6155–6165.
- Foster, J. L., and Garcia, J. V. (2008). HIV-1 Nef at the crossroads. *Retrovirology* 22, 84.
- Fujita, M., Otsuka, M., Miyoshi, M., Khamsri, B., Nomaguchi, M., and Adachi, A. (2008a). Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages. *J. Virol.* 82, 7752–7756.
- Fujita, M., Otsuka, M., Nomaguchi, M., and Adachi, A. (2008b). Functional region mapping of HIV-2 Vpx protein. *Microbes Infect.* 10, 1387–1392.
- Fujita, M., Otsuka, M., Nomaguchi, M., and Adachi, A. (2010). Multifaceted activity of HIV Vpr/Vpx proteins: the current view of their virological functions. *Rev. Med. Virol.* 20, 68–76.
- Gibbs, J. S., Regier, D. A., and Desrosiers, R. C. (1994). Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. *AIDS Res. Hum. Retroviruses* 10, 607–616.
- Goila-Gaur, R., and Strebel, K. (2008). HIV-1 Vif, APOBEC, and intrinsic immunity. *Retrovirology* 5, 51.
- Goldstone, D. C., Ennis-Adeniran, V., Hedden, J. J., Groom, H. C., Rice, G. I., Christodoulou, E., Walker, P. A., Kelly, G., Haire, L. F., Yap, M. W., de Carvalho, L. P., Stoye, J. P., Crow, Y. J., Taylor, I. A., and Webb, M. (2011). HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. *Nature* 480, 379–382.
- Gramberg, T., Sunseri, N., and Landau, N. R. (2010). Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx. *J. Virol.* 84, 1387–1396.
- Guyader, M., Emerman, M., Montagnier, L., and Peden, K. (1989). VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. *EMBO J.* 8, 1169–1175.
- Hartman, Z. C., Kiang, A., Everett, R. S., Serra, D., Yang, X. Y., Clay, T. M., and Amalfitano, A. (2007). Adenovirus infection triggers rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. *J. Virol.* 81, 1796–1812.
- Hirsch, V. M., Sharkey, M. E., Brown, C. R., Brichacek, B., Goldstein, S., Wakefield, J., Byrum, R., Elkins, W. R., Hahn, B. H., Lifson, J. D., and Stevenson, M. (1998). Vpx is required for dissemination and pathogenesis of SIVSMPBj: evidence of macrophage-dependent viral amplification. *Nat. Med.* 4, 1401–1408.
- Hrecka, K., Hao, C., Gierszewska, M., Swanson, S. K., Kesik-Brodacka, M., Srivastava, S., Florens, L., Washburn, M. P., and Skowronski, J. (2011). Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. *Nature* 474, 658–661.
- Jacquot, G., Le Rouzic, E., David, A., Mazzolini, J., Bouchet, J., Bouaziz, S., Niedergang, F., Pancino, G., and Benichou, S. (2007). Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. *Retrovirology* 4, 84.
- Jin, L., Zhou, Y., and Ratner, L. (2001). HIV type 2 Vpx interaction with Gag and incorporation into virus-like particles. *AIDS Res. Hum. Retroviruses* 17, 105–111.
- Kappes, J. C., Conway, J. A., Lee, S.-W., Shaw, G. M., and Hahn, B. H. (1991). Human immunodeficiency virus type 2 vpx protein augments viral infectivity. *Virology* 184, 197–209.
- Kaushik, R., Zhu, X., Stranska, R., Wu, Y., and Stevenson, M. (2009). A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. *Cell Host Microbe* 6, 68–80.
- Kawamura, M., Sakai, H., and Adachi, A. (1994). Human immunodeficiency virus Vpx is required for the early phase of replication in peripheral blood mononuclear cells. *Microbiol. Immunol.* 38, 871–878.
- Khamsri, B., Murao, F., Yoshida, A., Sakurai, A., Uchiyama, T., Shirai, H., Matsuo, Y., Fujita, M., and Adachi, A. (2006). Comparative study on the structure and cytopathogenic activity of HIV Vpr/Vpx proteins. *Microbes Infect.* 8, 10–15.
- Kitamura, S., Ode, H., and Iwatani, Y. (2011). Structural features of antiviral APOBEC3 proteins are linked to their functional activities. *Front. Microbiol.* 2:258. doi:10.3389/fmicb.2011.00258
- Laguette, N., Brégnard, C., Benichou, S., and Basmaciogullari, S. (2010). Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. *Mol. Aspects Med.* 31, 418–433.
- Laguette, N., Sobhian, B., Casartelli, N., Ringgaard, M., Chable-Bessia, C., Segéral, E., Yatim, A., Emiliani, S., Schwartz, O., and Benkirane, M. (2011). SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. *Nature* 474, 654–657.
- Lahouassa, H., Daddacha, W., Hofmann, H., Ayinde, D., Logue, E. C., Dragin, L., Bloch, N., Maudet, C., Bertrand, M., Gramberg, T., Pancino, G., Priet, S., Canard, B., Laguette, N., Benkirane, M., Transy, C., Landau, N. R., Kim, B., and Margottin-Goguet, F. (2012). SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. *Nat. Immunol.* 13, 223–228.
- Li, N., Zhang, W., and Cao, X. (2000). Identification of human homologue of mouse IFN- γ induced protein from human dendritic cells. *Immunol. Lett.* 74, 221–224.
- Lim, E. S., Fregoso, O. I., McCoy, C. O., Matsen, F. A., Malik, H. S., and Emerman, M. (2012). The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. *Cell Host Microbe* 11, 194–204.
- Mahalingam, S., Van Tine, B., Santiago, M. L., Gao, F., Shaw, G. M., and Hahn, B. H. (2001). Functional analysis of the simian immunodeficiency virus Vpx protein: identification of packaging determinants and a novel nuclear targeting domain. *J. Virol.* 75, 362–374.
- Neil, S. J., Zang, T., and Bieniasz, P. D. (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. *Nature* 451, 425–430.
- Nomaguchi, M., Fujita, M., and Adachi, A. (2008). Role of HIV-1 Vpu protein for virus spread and pathogenesis. *Microbes Infect.* 10, 960–967.
- Pancio, H. A., Vander Heyden, N., and Ratner, L. (2000). The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells. *J. Virol.* 74, 6162–6167.
- Park, I.-W., and Sodroski, J. (1995). Amino acid sequence requirements for the incorporation of the Vpx protein of simian immunodeficiency virus into virion particle. *J. Acquir. Immune. Defic. Syndr. Hum. Retrovirology* 10, 506–510.
- Planelles, V. (2011). Restricted access to myeloid cells explained. *Viruses* 3, 1624–1633.
- Planelles, V., Jowett, J. B., Li, Q. X., Xie, Y., Hahn, B., and Chen, I. S. (1996). Vpr-induced cell cycle arrest is conserved among primate lentiviruses. *J. Virol.* 70, 2516–2524.
- Powell, R. D., Holland, P. J., Hollis, T., and Perrino, F. W. (2011). Aicardi-Goutières syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. *J. Biol. Chem.* 286, 43596–43600.
- Prehaud, C., Megret, F., Lafage, M., and Lafon, M. (2005). Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. *J. Virol.* 79, 12893–12904.
- Rice, G. I., Bond, J., Asipu, A., Brunette, R. L., Manfield, I. W., Carr, I. M., Fuller, J. C., Jackson, R. M., Lamb, T., Briggs, T. A., Ali, M., Gornall, H., Couthard, L. R., Aeby, A., Attard-Montalto, S. P., Bertini, E., Bodeimer, C., Brockmann, K., Bruetow, L. A., Corry, P. C., Desguerre, I., Fazzi, E., Cazorla, A. G., Gener, B., Hamel, B. C., Heiberger, A., Hunter, M., van der Knaap, M. S., Kumar, R., Lagae, L., Landrieu, P. G., Lourenco, C. M., Marom, D., McDermott, M. F., van der Merwe, W., Orcesi, S., Prendiville, J. S., Rasmussen, M., Shalev, S. A., Soler, D. M., Shinawi, M., Spiegel, R., Tan, T. Y., Vanderver, A., Wakeling, E. L., Wassmer, E., Whittaker, E., Lebon, P., Stetson, D. B., Bonthron, D. T., and Crow, Y. J. (2009). Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. *Nat. Genet.* 41, 829–832.
- Selig, L., Benichou, S., Rogel, M. E., Wu, L. I., Vodicka, M. A., Sire, J., Benarous, R., and Emerman, M. (1997). Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. *J. Virol.* 71, 4842–4846.
- Sharifi, H. J., Furuya, A. M., and de Noronha, C. M. (2012). The role of HIV-1 Vpr in promoting the infection of nondividing cells and in cell

- cycle arrest. *Curr. Opin. HIV AIDS* 7, 187–194.
- Sharova, N., Wu, Y., Zhu, X., Stanska, R., Kaushik, R., Sharkey, M., and Stevenson, M. (2008). Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. *PLoS Pathog.* 4, e1000057. doi:10.1371/journal.ppat.1000057
- Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* 418, 646–650.
- Srivastava, S., Swanson, S. K., Manel, N., Florens, L., Washburn, M. P., and Skowronski, J. (2008). Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. *PLoS Pathog.* 4, e1000059. doi:10.1371/journal.ppat.1000059
- Stivahtis, G. L., Soares, M. A., Vodicka, M. A., Hahn, B. H., and Emerman, M. (1997). Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. *J. Virol.* 71, 4331–4338.
- Tokunaga, K., Ishimoto, A., Ikuta, K., and Adachi, A. (1997). Growth ability of auxiliary gene mutants of human immunodeficiency virus types 1 and 2 in unstimulated peripheral blood mononuclear cells. *Arch. Virol.* 142, 177–181.
- Tsurutani, N., Kubo, M., Maeda, Y., Ohashi, T., Yamamoto, N., Kan-nagi, M., and Masuda, T. (2000). Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. *J. Virol.* 74, 4795–4806.
- Ueno, F., Shiota, H., Miyaura, M., Yoshida, A., Sakurai, A., Tatsuki, J., Koyama, A. H., Akari, H., Adachi, A., and Fujita, M. (2003). Vpx and Vpr proteins of HIV-2 up-regulate the viral infectivity by a distinct mechanism in lymphocytic cells. *Microbes Infect.* 5, 387–395.
- Van Damme, N., Goff, D., Katsura, C., Jorgenson, R. L., Mitchell, R., Johnson, M. C., Stephens, E. B., and Guatelli, J. (2008). The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. *Cell Host Microbe* 3, 245–252.
- Yu, X.-F., Yu, Q.-C., Essex, M., and Lee, T.-H. (1991). The vpx gene of simian immunodeficiency virus facilitates efficient viral replication in fresh lymphocytes and macrophages. *J. Virol.* 65, 5088–5091.
- Zhao, D., Peng, D., Li, L., Zhang, Q., and Zhang, C. (2008). Inhibition of GIP3 expression found in the different display study on respiratory syncytial virus infection. *Viol. J.* 5, 114.
- Zhu, Y., Gelbard, H. A., Roshal, M., Pursell, S., Jamieson, B. D., and Planelles, V. (2001). Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. *J. Virol.* 75, 3791–3801.
- Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 25 April 2012; paper pending published: 16 May 2012; accepted: 25 July 2012; published online: 10 August 2012.
Citation: Fujita M, Nomaguchi M, Adachi A and Otsuka M (2012) SAMHD1-dependent and -independent functions of HIV-2/SIV Vpx protein. *Front. Microbio.* 3:297. doi: 10.3389/fmicb.2012.00297

This article was submitted to *Frontiers in Virology*, a specialty of *Frontiers in Microbiology*.

Copyright © 2012 Fujita, Nomaguchi, Adachi and Otsuka. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

